pharmaphorum3d
How can the pharma industry navigate issues in the global supply chain to minimise drug shortages?
The two primary exporters of Active Pharmaceutical ... as Valsartan, the active ingredient in many blood pressure medications. If a company’s submission to the FDA refers only to suppliers ...
BioSpace11d
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
Contract Pharma11d
Novartis to Acquire Anthos Therapeutics
Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...
Reuters11d
Novartis buys Blackstone's Anthos for up to $3.1 billion
Feb 11 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab ... rate cuts and other central banks do not, bankers and corporate advisers said. Marketscategory TSX falls as ...
The Boston Globe10d
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...
MedCity News11d
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
Novartis is expanding its prospects in cardiometabolic ... advantages over anticoagulants currently sold by some of its big pharmaceutical peers. According to deal terms announced Tuesday ...
pharmaphorum3d
A history of Novartis
Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...
The Hindu22d
U.S. FDA nod for Natco Pharma’s generic of Novartis drug
a generic version of Novartis Pharmaceutical Corporation’s Afinitor Disperz. Marketing partner for its abbreviated new drug application (ANDA), Breckenridge Pharmaceutical Inc., plans to launch ...
Wall Street Journal11d
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
Novartis NOVN0.30%increase ... The deal means the Swiss pharmaceutical company retakes control over a treatment candidate for blood clots it licensed to Anthos when the Boston-based firm was ...
Reuters22d
Novartis CEO says U.S. exit from global health programmes to affect millions
FRANKFURT, Jan 31 (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming ...
Yahoo Finance19d
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp ...
Business Wire11d
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...